Category Archives: Drugs

Novartis must end ‘bullying tactics’ over life-saving medicines, campaigners says

Global protests ahead of Novartis AGM in Switzerland tomorrow Call for new CEO to clean up company following scandals in Colombia and Greece Thursday 1 March 2018 – Swiss multinational Novartis today faced international calls from an alliance of health … Continue reading

Posted in Compulsory Licensing, Generics, Novartis Case, Uncategorized | Leave a comment

Health groups irked by Supreme Court order on vaccine PSUs; mull fresh petition

on behalf of the All India Drug Action Network (AIDAN) and co-petitioners 19 February 2018 Several health groups expressed their strong disappointment with the order of the Supreme Court (SC) of February 12, 2018, which refused to review or recall … Continue reading

Posted in Generics, Uncategorized | Leave a comment

Humira’s Best-Selling Drug Formula: Start at a High Price. Go Higher.

Humira is the best-selling prescription drug in the world. You may have seen the commercials. Because of Humira, a woman with rheumatoid arthritis can wash her puppy in the bathtub, another with colitis can stroll happily through a fair packed … Continue reading

Posted in Biologics/Biosimilars, Drug prices, Uncategorized | Leave a comment

Cancer Drug Price Rises 1, 400% With No Generic to Challenge It

By Peter Loftus, Wall Street Journal Since 2013, the price of a 40-year-old, off-patent cancer drug in the U.S. has risen 1,400%, putting the life-extending medicine out of reach for some patients. Introduced in 1976 to treat brain tumors and Hodgkin … Continue reading

Posted in Cancer, Drug prices, Generics, Price hikes, Uncategorized | Leave a comment

Rethinking IP in the TPP: Canadian Government Plays Key Role in Suspending Unbalanced Patent and Copyright Rules

Source: Years of disappointment in trade negotiations have left many Canadian intellectual property watchers hoping for the best, but expecting the worst when it comes to the IP provisions in trade deals. In earlier talks, Canadian negotiators would often advocate … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent Term Extension, TPP, TRIPS, TRIPS plus, Uncategorized | Leave a comment

Time for costly medicine monopolies to go from TPP trade talks

Source: |November 9, 2017 Negotiators from 11 countries have been racing to resurrect the near-dead Trans-Pacific Partnership Agreement before the Asia-Pacific Economic Cooperation (APEC) summit this weekend. The latest plan to get the controversial trade deal up and running … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent, TPP, Uncategorized | Leave a comment

India to oppose anti-generics proposals at RCEP meet

Source: LiveMint India stands firm in opposing proposals that could hinder global access to affordable generic drugs and life-saving vaccines South Korea and Japan have been pushing for proposals to extend drug and vaccine patent terms, a move that is … Continue reading

Posted in Data Exclusivity, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized, WTO | Leave a comment